Child-Safe mpox vaccine trial shows promise for younger ages
NCT ID NCT06549530
First seen Nov 24, 2025 · Last updated May 15, 2026 · Updated 23 times
Summary
This study tests whether the MVA-BN vaccine, already used in adults, works safely in children aged 2 to 12 to prevent mpox, smallpox, and similar viruses. About 460 participants, including children and adults, will receive two doses four weeks apart. Researchers will measure immune responses and monitor side effects over one year.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MONKEYPOX (MPOX) are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Epicentre Mbarara Research Centre
Mbarara, Uganda
-
Uganda Virus Research Institute
Entebbe, Uganda
-
University of Kinshasa
Kinshasa, Democratic Republic of the Congo
Conditions
Explore the condition pages connected to this study.